Name: Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection (Video) | JoVE Journal
Uploaded: 2020-05-24T14:30:00.000+00:00
Duration: 9 min 25 s
Description: Learn scarless recombinant vaccinia virus generation using host-range selection and fluorescent markers. This method enables efficient genetic modification for vaccine development and gene expression studies.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This project was funded by the National Institutes of Health (AI114851) to SR.

1. Generating the recombination vector
<ol>
	<li>Design primers to generate the selection cassette. Design each individual amplicon with overlapping sequences with neighboring amplicons and the vector to facilitate isothermal enzymatic assembly of DNA molecules, also called Gibson assembly, using any of several online primer design tools. 
	NOTE: This protocol can also be completed using traditional restriction endonuclease-based cloning methods. In that case, design primers with the appropriate restriction sites rather than with overlapping sequences.</li>
	<li>Using the primers designed in step 1.1, PCR amplify the following elements in order from 5&#8217; to 3&#8217; (Figure 1): ~500 nucleotides of the VACV genomic region 5&#8217; of E3L (5&#8217; arm), EGFP or the gene of interest, ~150 nucleotides from the VACV genomic region immediately 3&#8217; of E3L (short 3&#8217; arm), a synthetic early/late poxvirus promoter25, the mCherry-E3L fusion gene, and ~500 nucleotides from the VACV genomic region 3&#8217; of E3L including the short 3&#8217; arm (long 3&#8217; arm).
	<ol>
		<li>In a PCR tube, add the reagents in the following order for each amplicon: 17 &#956;L of DNase free water, 1.2 &#181;L of each primer (initial concentration = 10 &#956;M, final concentration = 0.5 &#956;M), 5 &#181;L of 5x PCR reaction buffer, template DNA (10 ng for amplicons amplified from plasmids: EGFP and E/L promoter-mCherry-E3L cassette; 100 ng for amplicons amplified from viral genomic DNA: 5&#8217; and 3&#8217; arms), and 0.5 &#181;L of DNA polymerase. Adjust the volume of water added for a final reaction volume of 50 &#956;L. 
		NOTE: The concentration of template DNA should be empirically determined, but we generally start with 10 ng/reaction.</li>
		<li>Place the tube(s) in a thermocycler, and melt the DNA at 98 &#176;C for 30 s, and then use 25 rounds of a three-step PCR protocol: 98 &#176;C for 5 s, 55 &#176;C for 10 s, and 72 &#176;C for 1 min. 
		NOTE: Determine the melting temperature based on the manufacturer&#8217;s suggested Tm for each primer set. Determine the appropriate extension time based on the length of each amplicon (1 minute/kb).</li>
	</ol>
	</li>
	<li>Visualize the amplification products on a 1% agarose gel. Add 10 &#956;L of each DNA product and 2 &#956;L of loading buffer to each well, and run at 8 V/cm for 1 h.</li>
	<li>Gel purify each amplicon using a DNA gel extraction kit and manufacturer&#8217;s protocol. Elute the amplicons from the column by adding 50 &#956;L of DNase free water and immediately centrifuging.</li>
	<li>Linearize the pUC19 cloning vector using EcoRI endonuclease digestion. To a tube, add 1 &#956;g of pUC19, water to a volume of 17 &#956;L, 2 L of reaction buffer, and 1 &#956;L (20 units) of EcoRI. Incubate at 37 &#176;C for 1 h.
	<ol>
		<li>Visualize the amplification products on a 1% agarose gel run at 8 V/cm for 1 h. Excise the band from the gel, and purify the product using the DNA gel extraction kit as described in step 1.4.</li>
	</ol>
	</li>
	<li>Ligate all of the individual, gel purified amplicons and the linearized vector using a master mix kit.
	<ol>
		<li>To a PCR tube, add 0.2 pmol of linearized pUC19 and each amplicon (5&#8217; arm, EGFP, short 3&#8217; arm, E/L promoter-mCherry-E3L cassette, 3&#8217;arm). Add DNase free water to a final volume of 10 &#956;L, and then add 10 &#956;L of DNA assembly master mix. Incubate samples at 50 &#176;C for 1 h.</li>
	</ol>
	</li>
	<li>Transform chemically competent E. coli with 2 &#956;L of the assembled product from step 1.6 as previously described26,27. Plate 100 &#956;L of the transformed cells on LB agarose plates containing 100 &#956;g/mL ampicillin. Incubate the plates overnight at 37 &#176;C.</li>
	<li>Pick well-isolated colonies and transfer individual colonies to tubes containing Luria broth with 100 &#956;g/mL ampicillin. Incubate the tubes overnight at 37 &#176;C while shaking at 225 rpm.</li>
	<li>Isolate the plasmids from the overnight culture using a plasmid miniprep kit. Check the concentration and purity of the DNA using a spectrophotometer. An A260/A280 ratio between 1.8 and 2.0 is acceptable.</li>
	<li>Submit the plasmids for Sanger sequencing to determine whether the desired cloning product is correct. Store the DNA at -20 &#176;C.</li>
</ol>
2. Generating the recombinant virus
<ol>
	<li>Infect a confluent monolayer of suitable cells with the virus to be recombined at a multiplicity of infection of 1.0 (MOI = 1.0) in a 6-well plate. Incubate the infected cells at 37 &#176;C and 5% CO2 for 1 h. Then aspirate the medium and replace it with fresh DMEM. Incubate the infected cells at 37 &#176;C and 5% CO2. 
	NOTE: For replication competent viruses such as a vaccinia virus that lacks K3L22, a cell line such as European rabbit kidney cell line RK13 (ATCC #CCL-37) or BSC-40 is appropriate. However, for replication deficient viruses, such as the virus described in this paper lacking both PKR antagonists E3L and K3L, a complementing cell line expressing these two genes in trans or PKR knock-down or knock-out cells are required.</li>
	<li>Transfect the infected cells with 500 ng of the vector generated and validated in step 1.10 using a commercially available transfection reagent following the manufacturer&#8217;s protocol. Incubate the cells at 37 &#176;C and 5% CO2 for 48 h. 
	NOTE: If using a vaccinia virus lacking both E3L and K3L, PKR-mediated selective pressure will drive selection of recombined viruses and maintain expression of the mCherry-E3L fusion protein in these cells. If desired, it should also be possible to PCR amplify only the insert to use for transfection instead of the whole plasmid.</li>
	<li>48 hours post-infection, harvest the infected monolayer. In some cases, the cells can be harvested by pipetting, but if they are still tightly adhered, harvest them with a cell scraper. Freeze-thaw the cells three times, and then sonicate the lysates for 15 s at 50% amplitude. Store this lysate at -80 &#176;C until ready to use.</li>
	<li>Serially 10-fold dilute the lysate harvested in step 2.3 from 10-1 to 10-6 by adding 120 &#956;L of the lysate to 1080 &#956;L of DMEM (10-1), and then adding 120 &#956;L of this dilution to 1080 &#956;L of DMEM (10-2), and repeating this process four more times. Add 1 mL of each dilution to an individual, confluent well of a PKR competent cell line, in this case RK13 cells.
	<ol>
		<li>Incubate the infected cells at 37 &#176;C and 5% CO2 for 1 h. Then aspirate the medium and replace it with fresh DMEM Incubate the infected cells at 37 &#176;C and 5% CO2.</li>
	</ol>
	</li>
	<li>24 to 48 hours post-infection, identify recombinant viruses by fluorescence microscopy. Plaques from recombinant viruses express red fluorescence due to integration the mCherry-E3L fusion gene (Figure 2). If a virus devoid of PKR inhibitors was used initially, all plaques will contain recombinant virus.</li>
	<li>Plaque purify recombinant viruses three times on RK13 cells. After the final round of plaque purification, all plaques should express red fluorescence.</li>
	<li>Infect a confluent 6-well plate of RK13 cells expressing the VACV PKR inhibitors E3L and K3L (RK13+E3L+K3L cells28) with the plaque-purified red fluorescing virus from step 2.6. Aim for approximately 50-100 plaques per well. 
	NOTE: These cells provide the VACV PKR antagonists in trans and alleviate the PKR-mediated selective pressure to maintain the mCherry-E3L fusion gene, thus promoting &#8220;scarless&#8221; generation of the recombinant virus.</li>
	<li>Identify collapsed viruses by fluorescence microscopy using an EVOS2 microscope, and a GFP filter cube (Excitation: 470/22, Emission: 525/50) and a RFP filter cube (Excitation: 531/40, Emission: 593/40). 
	NOTE: The frequency at which the mCherry-E3L fusion gene is lost is approximately 2.5% (Table 2). If EGFP is not included as a marker gene, plaques from mutant viruses that have lost the mCherry-E3L fusion gene will be colorless.</li>
	<li>Plaque purify green-only (VC-R4) or colorless plaques (E3L) three times on RK13+E3L+K3L cells. Ensure that no plaques fluoresce red.</li>
	<li>Confirm the loss of mCherry-E3L and the presence of the expected mutation by PCR and Sanger sequencing. 
	NOTE: If the gene or mutation of interest does not have PKR inhibitory activity, recombinant viruses must be grown on RK13+E3L+K3L cells or an equivalent PKR-inhibited or PKR deficient cell line (Figure 3).</li>
</ol>

<ol><li>Brochier, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Large-scale+eradication+of+rabies+using+recombinant+vaccinia-rabies+vaccine%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine.</a> Nature. 354 (6354), 520-522 (1991).</li>
<li>Pastoret, P. P., Brochier, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+development+and+use+of+a+vaccinia-rabies+recombinant+oral+vaccine+for+the+control+of+wildlife+rabies%3B+a+link+between+Jenner+and+Pasteur%5BTitle%5D)+AND+%22Epidemiology+and+Infection%22%5BJournal%5D)">The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur.</a> Epidemiology and Infection. 116 (3), 235-240 (1996).</li>
<li>Chan, W. M., McFadden, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Oncolytic+Poxviruses%5BTitle%5D)+AND+%22Annual+review+of+virology%22%5BJournal%5D)">Oncolytic Poxviruses.</a> Annual review of virology. 1 (1), 119-141 (2014).</li>
<li>Nguyen, D. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Vaccinia+virus-mediated+expression+of+human+erythropoietin+in+tumors+enhances+virotherapy+and+alleviates+cancer-related+anemia+in+mice%5BTitle%5D)+AND+%22Molecular+Therapy%22%5BJournal%5D)">Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.</a> Molecular Therapy. 21 (11), 2054-2062 (2013).</li>
<li>Frentzen, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Anti-VEGF+single-chain+antibody+GLAF-1+encoded+by+oncolytic+vaccinia+virus+significantly+enhances+antitumor+therapy%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy.</a> Proceedings of the National Academy of Sciences of the United States of America. 106 (31), 12915-12920 (2009).</li>
<li>Pastoret, P. P., Vanderplasschen, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Poxviruses+as+vaccine+vectors%5BTitle%5D)+AND+%22Comparative+Immunology%2C+Microbiology+and+Infectious+Diseases%22%5BJournal%5D)">Poxviruses as vaccine vectors.</a> Comparative Immunology, Microbiology and Infectious Diseases. 26 (5-6), 343-355 (2003).</li>
<li>COLLIER, L. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+development+of+a+stable+smallpox+vaccine%5BTitle%5D)+AND+%22The+Journal+of+Hygiene%22%5BJournal%5D)">The development of a stable smallpox vaccine.</a> The Journal of Hygiene. 53 (1), 76-101 (1955).</li>
<li>Weir, J. P., Bajszár, G., Moss, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mapping+of+the+vaccinia+virus+thymidine+kinase+gene+by+marker+rescue+and+by+cell-free+translation+of+selected+mRNA%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA.</a> Proceedings of the National Academy of Sciences of the United States of America. 79 (4), 1210-1214 (1982).</li>
<li>Mackett, M., Smith, G. L., Moss, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Vaccinia+virus%3A+a+selectable+eukaryotic+cloning+and+expression+vector%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Vaccinia virus: a selectable eukaryotic cloning and expression vector.</a> Proceedings of the National Academy of Sciences of the United States of America. 79 (23), 7415-7419 (1982).</li>
<li>Nakano, E., Panicali, D., Paoletti, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Molecular+genetics+of+vaccinia+virus%3A+demonstration+of+marker+rescue%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Molecular genetics of vaccinia virus: demonstration of marker rescue.</a> Proceedings of the National Academy of Sciences of the United States of America. 79 (5), 1593-1596 (1982).</li>
<li>Falkner, F. G., Moss, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Transient+dominant+selection+of+recombinant+vaccinia+viruses%5BTitle%5D)+AND+%22Journal+of+Virology%22%5BJournal%5D)">Transient dominant selection of recombinant vaccinia viruses.</a> Journal of Virology. 64 (6), 3108-3111 (1990).</li>
<li>Staib, C., Drexler, I., Ohlmann, M., Wintersperger, S., Erfle, V., Sutter, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Transient+Host+Range+Selection+for+Genetic+Engineering+of+Modified+Vaccinia+Virus+Ankara%5BTitle%5D)+AND+%22BioTechniques%22%5BJournal%5D)">Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara.</a> BioTechniques. 28 (6), 1137-1148 (2000).</li>
<li>Staib, C., Drexler, I., Sutter, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Construction+and+Isolation+of+Recombinant+MVA%5BTitle%5D)+AND+%22Vaccinia+Virus+and+Poxvirology%22%5BJournal%5D)">Construction and Isolation of Recombinant MVA.</a> Vaccinia Virus and Poxvirology. , 77-99 (2004).</li>
<li>Di Lullo, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Marker+gene+swapping+facilitates+recombinant+Modified+Vaccinia+Virus+Ankara+production+by+host-range+selection%5BTitle%5D)+AND+%22Journal+of+Virological+Methods%22%5BJournal%5D)">Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection.</a> Journal of Virological Methods. 156 (1-2), 37-43 (2009).</li>
<li>Pfaller, C. K., Li, Z., George, C. X., Samuel, C. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Protein+kinase+PKR+and+RNA+adenosine+deaminase+ADAR1%3A+New+roles+for+old+players+as+modulators+of+the+interferon+response%5BTitle%5D)+AND+%22Current+Opinion+in+Immunology%22%5BJournal%5D)">Protein kinase PKR and RNA adenosine deaminase ADAR1: New roles for old players as modulators of the interferon response.</a> Current Opinion in Immunology. 23 (5), 573-582 (2011).</li>
<li>Bevilacqua, P. C., George, C. X., Samuel, C. E., Cech, T. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Binding+of+the+protein+kinase+PKR+to+RNAs+with+secondary+structure+defects%3A+Role+of+the+tandem+A+-+G+mismatch+and+noncontigous+helixes%5BTitle%5D)+AND+%22Biochemistry%22%5BJournal%5D)">Binding of the protein kinase PKR to RNAs with secondary structure defects: Role of the tandem A - G mismatch and noncontigous helixes.</a> Biochemistry. 37 (18), 6303-6316 (1998).</li>
<li>Krishnamoorthy, T., Pavitt, G. D., Zhang, F., Dever, T. E., Hinnebusch, A. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tight+Binding+of+the+Phosphorylated+Subunit+of+Initiation+Factor+2+%28eIF2%29+to+the+Regulatory+Subunits+of+Guanine+Nucleotide+Exchange+Factor+eIF2B+Is+Required+for+Inhibition+of+Translation+Initiation%5BTitle%5D)+AND+%22Molecular+and+Cellular+Biology%22%5BJournal%5D)">Tight Binding of the Phosphorylated Subunit of Initiation Factor 2 (eIF2) to the Regulatory Subunits of Guanine Nucleotide Exchange Factor eIF2B Is Required for Inhibition of Translation Initiation.</a> Molecular and Cellular Biology. 21 (15), 5018-5030 (2001).</li>
<li>Rothenburg, S., Georgiadis, M. M., Wek, R. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Evolution+of+eIF2%CE%B1+kinases%3A+Adapting+translational+control+to+diverse+stresses%5BTitle%5D)+AND+%22Evolution+of+the+Protein+Synthesis+Machinery+and+Its+Regulation%22%5BJournal%5D)">Evolution of eIF2α kinases: Adapting translational control to diverse stresses.</a> Evolution of the Protein Synthesis Machinery and Its Regulation. , 235-260 (2016).</li>
<li>Bratke, K. A., McLysaght, A., Rothenburg, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+survey+of+host+range+genes+in+poxvirus+genomes%5BTitle%5D)+AND+%22Infection%2C+Genetics+and+Evolution%22%5BJournal%5D)">A survey of host range genes in poxvirus genomes.</a> Infection, Genetics and Evolution. 14, 406-425 (2013).</li>
<li>Chang, H. W., Watson, J. C., Jacobs, B. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+E3L+gene+of+vaccinia+virus+encodes+an+inhibitor+of+the+interferon-induced%2C+double-stranded+RNA-dependent+protein+kinase%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences%22%5BJournal%5D)">The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase.</a> Proceedings of the National Academy of Sciences. 89 (11), 4825-4829 (1992).</li>
<li>Romano, P. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Inhibition+of+double-stranded+RNA-dependent+protein+kinase+PKR+by+vaccinia+virus+E3%3A+role+of+complex+formation+and+the+E3+N-terminal+domain%5BTitle%5D)+AND+%22Molecular+and+Cellular+Biology%22%5BJournal%5D)">Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain.</a> Molecular and Cellular Biology. 18 (12), 7304-7316 (1998).</li>
<li>Beattie, E., Tartaglia, J., Paoletti, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Vaccinia+virus-encoded+eIF-2+alpha+homolog+abrogates+the+antiviral+effect+of+interferon%5BTitle%5D)+AND+%22Virology%22%5BJournal%5D)">Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon.</a> Virology. 183 (1), 419-422 (1991).</li>
<li>Park, C., Peng, C., Brennan, G., Rothenburg, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Species-specific+inhibition+of+antiviral+protein+kinase+R+by+capripoxviruses+and+vaccinia+virus%5BTitle%5D)+AND+%22Annals+of+the+New+York+Academy+of+Sciences%22%5BJournal%5D)">Species-specific inhibition of antiviral protein kinase R by capripoxviruses and vaccinia virus.</a> Annals of the New York Academy of Sciences. 1438 (1), 18-29 (2019).</li>
<li>Rothenburg, S., Brennan, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Species-Specific+Host-Virus+Interactions%3A+Implications+for+Viral+Host+Range+and+Virulence%5BTitle%5D)+AND+%22Trends+in+Microbiology%22%5BJournal%5D)">Species-Specific Host-Virus Interactions: Implications for Viral Host Range and Virulence.</a> Trends in Microbiology. , (2019).</li>
<li>Chakrabarti, S., Sisler, J. R., Moss, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Compact%2C+synthetic%2C+vaccinia+virus+early%2Flate+promoter+for+protein+expression%5BTitle%5D)+AND+%22BioTechniques%22%5BJournal%5D)">Compact, synthetic, vaccinia virus early/late promoter for protein expression.</a> BioTechniques. 23 (6), 1094-1097 (1997).</li>
<li>Chung, C. T., Niemela, S. L., Miller, R. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((One-step+preparation+of+competent+Escherichia+coli%3A+Transformation+and+storage+of+bacterial+cells+in+the+same+solution+%28recombinant+DNA%29%5BTitle%5D)+AND+%22Biochemistry%22%5BJournal%5D)">One-step preparation of competent Escherichia coli: Transformation and storage of bacterial cells in the same solution (recombinant DNA).</a> Biochemistry. 86, 2172-2175 (1989).</li>
<li>Chung, C. T., Miller, R. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Preparation+and+storage+of+competent+Escherichia+coli+cells%5BTitle%5D)+AND+%22Methods+in+Enzymology%22%5BJournal%5D)">Preparation and storage of competent Escherichia coli cells.</a> Methods in Enzymology. 218, 621-627 (1993).</li>
<li>Rahman, M. M., Liu, J., Chan, W. M., Rothenburg, S., McFadden, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Myxoma+Virus+Protein+M029+Is+a+Dual+Function+Immunomodulator+that+Inhibits+PKR+and+Also+Conscripts+RHA%2FDHX9+to+Promote+Expanded+Host+Tropism+and+Viral+Replication%5BTitle%5D)+AND+%22PLOS+Pathogens%22%5BJournal%5D)">Myxoma Virus Protein M029 Is a Dual Function Immunomodulator that Inhibits PKR and Also Conscripts RHA/DHX9 to Promote Expanded Host Tropism and Viral Replication.</a> PLOS Pathogens. 9 (7), 1003465(2013).</li>
<li>Evans, D. H., Stuart, D., McFadden, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High+levels+of+genetic+recombination+among+cotransfected+plasmid+DNAs+in+poxvirus-infected+mammalian+cells%5BTitle%5D)+AND+%22Journal+of+Virology%22%5BJournal%5D)">High levels of genetic recombination among cotransfected plasmid DNAs in poxvirus-infected mammalian cells.</a> Journal of Virology. 62 (2), 367-375 (1988).</li>
<li>Ball, L. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High-frequency+homologous+recombination+in+vaccinia+virus+DNA%5BTitle%5D)+AND+%22Journal+of+Virology%22%5BJournal%5D)">High-frequency homologous recombination in vaccinia virus DNA.</a> Journal of Virology. 61 (6), 1788-1795 (1987).</li>
<li>Spyropoulos, D. D., Roberts, B. E., Panicali, D. L., Cohen, L. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Delineation+of+the+viral+products+of+recombination+in+vaccinia+virus-infected+cells%5BTitle%5D)+AND+%22Journal+of+Virology%22%5BJournal%5D)">Delineation of the viral products of recombination in vaccinia virus-infected cells.</a> Journal of Virology. 62 (3), 1046-1054 (1988).</li>
<li>Liu, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Transient+dominant+host-range+selection+using+Chinese+hamster+ovary+cells+to+generate+marker-free+recombinant+viral+vectors+from+vaccinia+virus%5BTitle%5D)+AND+%22BioTechniques%22%5BJournal%5D)">Transient dominant host-range selection using Chinese hamster ovary cells to generate marker-free recombinant viral vectors from vaccinia virus.</a> BioTechniques. 62 (4), 183-187 (2017).</li>
</ol>

The authors declare no competing financial interests.

Here we present a variation of a transient marker selection strategy 32 to generate recombinant vaccinia viruses without retaining foreign DNA in the final recombinant virus. Our strategy uses selective pressure mediated by the host antiviral protein PKR rather than other forms of selective pressure such as antibiotics. The use of host antiviral genes eliminates the possibility of chemically induced phenotypic changes in the cells, or increased risk of mutation due to selection drugs. Furthermore,...

Vaccinia virus (VACV) was instrumental for the first successful eradication of a human pathogen, variola virus (VARV), from nature. Ever since the extermination of variola virus, poxviruses including VACV have continued to be useful therapeutic viruses for both human and animal medicine. For example, a VACV-based rabies virus vaccine has been very effective in preventing transmission of sylvatic rabies in Europe1 and the United States2. More recently, recombinant poxviruses expressing a variety of anti-tumor molecules (e.g., single-chain antibodies or human erythropoietin) have seen encouraging success as oncolytic agents3,4,5. VACV is particularly attractive as a vector because it is readily amenable to genetic manipulation, possesses a broad host range, and it is stable under a variety of conditions, allowing easy transportation and vaccine viability in the field6,7. While multiple techniques have been developed to generate recombinant VACV for laboratory experiments and vaccine generation, current strategies to generate these viruses have notable limitations.
Because of the utility of VACV, multiple strategies to generate recombinant viruses have been developed. The first strategy employs homologous recombination to introduce a cassette including the transgene and a selectable marker gene such as an antibiotic resistance gene. The cassette is flanked by two ~500 nucleotides (nt) or larger arms directing the gene to a specific site in the viral genome, which is then stably integrated by double crossover events8,9,10. This strategy is rapid and efficient; however, it results in extra genetic material in the form of the marker gene that may produce unexpected effects. Furthermore, there is a practical upper limit to the number of transgenes that can be introduced limited by the number of unique selectable markers available. Transient dominant selection (TDS) strategies have addressed this issue by facilitating the generation of &#34;scarless&#34; recombinant viruses11. Using this strategy, a plasmid containing a mutant VACV gene and a selectable marker gene are integrated into the viral genome, but without additional flanking VACV DNA. This approach results in transient integration of the entire plasmid and duplication of the VACV gene as a result of integration by a single crossover event. This intermediate is stable as long as it is maintained under selection pressure, permitting enrichment of this construct. When selection is removed, the VACV duplication enables a second crossover event that results in the removal of the plasmid and subsequent formation of either the wild type (wt) or recombinant virus in an approximate 50:50 ratio. While TDS generates recombinant viruses without requiring the stable introduction of foreign DNA, multiple virus clones must be screened for the expected mutation by sequencing analysis, a potentially time consuming and costly step.
Here, we present an approach to generating recombinant poxviruses combining the best aspects of each of these approaches, similar to an approach that has been described for the replication incompetent modified vaccinia Ankara12,13,14. This strategy combines visual and host range selection to rapidly generate recombinant viruses by double crossover events, and subsequently eliminate the selectable marker gene by homologous recombination. This approach permits the rapid generation of mutants mediated by homologous recombination, with the &#34;scarless&#34; nature of TDS approaches, while not requiring a subsequent screening step to distinguish wild type and mutant viruses. Our method also uses host range selection in place of antibiotic selection, eliminating the risk of chemically induced phenotypic changes in the cell line. For this approach, we have chosen to use the host antiviral protein kinase R (PKR) as the selective agent to generate recombinant VACV. PKR is expressed as an inactive monomer in most cell types15. Upon binding double-stranded RNA (dsRNA) at the N-terminal dsRNA-binding domains, PKR dimerizes and is autophosphorylated16. This active form of PKR phosphorylates the alpha subunit of the eukaryotic initiation factor 2 (eIF2), ultimately inhibiting delivery of initiator methionyl-tRNA to the ribosome, thereby preventing intracellular translation and broadly inhibiting the replication of many virus families17,18.
In response to the broad and potent antiviral activity of PKR, many viruses have evolved at least one strategy to prevent PKR activation. Most poxviruses express two PKR antagonists, encoded by the E3L and K3L genes in VACV, which antagonize PKR through two distinct mechanisms19. E3 prevents PKR homodimerization by binding double-stranded RNA20,21, while K3 acts as a pseudosubstrate inhibitor by binding directly to activated PKR and thereby inhibiting interaction with its substrate eIF2&#945;22. Importantly, these two PKR antagonists do not necessarily inhibit PKR from all species. For example, the K3 homolog from the sheeppox virus strongly inhibited PKR from sheep, whereas the sheeppox E3 homolog did not show considerable PKR inhibition23,24. In this study, we present a method to use PKR-mediated selective pressure combined with fluorescence selection to generate a VACV recombinant deleted for E3L and K3L (VC-R4), which cannot replicate in PKR competent cells derived from diverse species. This recombinant virus provides an excellent background for rapid generation of recombinant viruses expressing genes under control of the native E3L promoter.

<table><tbody><tr><td>2X-Q5 Master Mix</td><td>NEB</td><td>M0492L</td><td>High-fidelity polymerase used in PCR</td></tr><tr><td>Ampicillin</td><td>ThermoFisher Scientific</td><td>11593027</td><td>Bacterial selective agent</td></tr><tr><td>Disposable Cell Scrapers</td><td>ThermoFisher Scientific</td><td>08-100-242</td><td>Cell scraper to harvest infected cells</td></tr><tr><td>EVOS FL Auto 2 Cell imaging system</td><td>ThermoFisher Scientific</td><td>AMAFD2000</td><td>Fluorescent microscope</td></tr><tr><td>EVOS Light Cube, GFP</td><td>ThermoFisher</td><td>AMEP4651</td><td>GFP Cube</td></tr><tr><td>EVOS Light Cube, RFP</td><td>ThermoFisher</td><td>AMEP4652</td><td>RFP Cube</td></tr><tr><td>GenJet</td><td>SignaGen Laboratories</td><td>SL100489</td><td>Transfection reagent</td></tr><tr><td>Luria Bertani (LB) Broth</td><td>Gibco</td><td>10855021</td><td>Bacterial growth medium</td></tr><tr><td>Monarch DNA gel extraction kit</td><td>NEB</td><td>T1020L</td><td>Gel purification kit used to purify amplicons and linearized vectors</td></tr><tr><td>Monarch Plasmid Miniprep kit</td><td>NEB</td><td>T1010L</td><td>Miniprep kit ussed to purify plasmids</td></tr><tr><td>NanoDrop One</td><td>ThermoFisher Scientific</td><td>ND-ONE-W</td><td>Spectrophotometer used to measure RNA and DNA concentration</td></tr><tr><td>NEBuilder Master Mix</td><td>NEB</td><td>E2621L</td><td>Isothermal enzymatic assembly kit used to generate the recombination vector</td></tr><tr><td>Q500 Sonicator</td><td>Qsonica</td><td>Q500-110</td><td>Sonicator for virus lysates</td></tr><tr><td>RK13 cells</td><td>ATCC</td><td>CCL-37</td><td>Rabbit kidney cells</td></tr><tr><td>VWR Multiwell Cell Culture plates</td><td>VWR</td><td>10062-892</td><td>Cell culture plates</td></tr></tbody></table>

rapid, seamless generation of recombinant poxviruses using host range and visual selection

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Vaccinia virus (VACV) was instrumental in eradicating variola virus (VARV), the causative agent of smallpox, from nature. Since its first use as a vaccine, VACV has been developed as a vector for therapeutic vaccines and as an oncolytic virus. These applications take advantage of VACV&#8217;s easily manipulated genome and broad host range as an outstanding platform to generate recombinant viruses with a variety of therapeutic applications. Several methods have been developed to generate recombinant VACV, including marker selection methods and transient dominant selection. Here, we present a refinement of a host range selection method coupled with visual identification of recombinant viruses. Our method takes advantage of selective pressure generated by the host antiviral protein kinase R (PKR) coupled with a fluorescent fusion gene expressing mCherry-tagged E3L, one of two VACV PKR antagonists. The cassette, including the gene of interest and the mCherry-E3L fusion is flanked by sequences derived from the VACV genome. Between the gene of interest and mCherry-E3L is a smaller region that is identical to the first ~150 nucleotides of the 3&#8217; arm, to promote homologous recombination and loss of the mCherry-E3L gene after selection. We demonstrate that this method permits efficient, seamless generation of rVACV in a variety of cell types without requiring drug selection or extensive screening for mutant viruses.

We used the procedure diagrammed in Figure 1 to generate a VACV lacking both PKR antagonists E3L and K3L, by replacing E3L with EGFP in a virus already deleted for K3L (vP872). Figure 2 shows red fluorescent plaques in PKR competent RK13 cells indicative of viral expression of mCherry-E3L, as well as EGFP expressed in RK13+E3L+K3L cells confirming the loss of E3L and collapse of the mCherry-E3L selection marker. Figure 3 confirms th...

This is a method to generate &#8220;scarless&#8221; recombinant vaccinia viruses using host-range selection and visual identification of recombinant viruses.

Vaccinia virus (VACV) was instrumental in eradicating variola virus (VARV), the causative agent of smallpox, from nature. Since its first use as a ...

Our method uses host range selection and fluorescent markers for the efficient and seamless generation of recombinant vaccinia virus in a variety of cell types. This technique combines the speed of homologous recombination with the scarless nature of transient dominant selection. In addition, we host range selection to eliminate the possibility of chemically induced changes. This method can also be used to modify vaccinia virus or other poxviruses to express foreign genes, for example, to generate vaccines. If you're performing this protocol with fluorescence selection only, you must ensure that you're screening enough viruses to detect a relatively rare recombinants without PKR-selective pressure. This method relies on the gain and loss of fluorescent markers to successfully select viruses that have acquired the recombination cassettes and to detect viruses that have scarlessly recombined.To generate a recombination vector, first add 17 microliters of DNase free water, 1.2 microliters of each primer, five microliters of 5x PCR reaction buffer, template DNA, and 0.5 microliters of DNA polymerase to one PCR tube per amplicon. Add additional DNase free water to bring the final volume in each tube to 50 microliters and place the tubes into a thermocycler.Melt the DNA at 98 degrees Celsius for 30 seconds before using 25 rounds of a three-step PCR protocol as indicated. To visualize the amplification products on a 1% agarose gel, add 10 microliters of each DNA product and 2 microliters of loading buffer to each well. Run the gel for one hour at eight volts per centimeter.At the end of the run, use a DNA gel extraction kit according to the manufacturer's protocol to gel purify each amplicon. Elute the amplicons from the column with 50 microliters of DNase free water and immediate centrifugation. To linearize a cloning vector, first add one microgram of the vector, 17 microliters of DNase free water, 2 microliters of reaction buffer, and 1 microliter of EcoRI to a tube for a one hour incubation at 37 degrees Celsius.At the end of the incubation, add 0.2 picomoles of the linearized vector 10 microliters of DNase free water, and 10 microliters of DNA assembly master mix to each isolated amplicon. Incubate samples at 50 degrees Celsius for one hour. At the end of the incubation, transform chemically competent E.coli with two microliters of the assembled product according to standard protocols.Plate 100 microliters of transformed cells onto LB agarose plates supplemented with 100 micrograms per milliliter of ampicillin. After overnight incubation at 37 degrees Celsius, select well-isolated colonies for inoculation in Luria broth supplemented with 100 micrograms per milliliter of ampicillin overnight at 37 degrees Celsius and 225 revolutions per minute. The next morning, use a plasmid miniprep kit to isolate the plasmids and check the concentration and purity of the DNA on a spectrophotometer. For recombinant virus generation, infect a confluent monolayer of suitable cells with the virus to be recombined at a multiplicity of infection of one in a six-well plate. And incubate the infected cells at 37 degrees Celsius and 5% carbon dioxide for one hour. At the end of the incubation, replace the supernatant in each well with fresh DMEM and using a commercially available transfection reagent according to the manufacturer's protocol add three micrograms of the recombination vector of interest to each well. Place the plate in the incubator for additional 48 hours before pooling the cells from each transfection condition into individual 1.5 milliliters tubes. Then freeze-thaw the pooled cells three times before sonicating the resulting lysates for 15 seconds at a 50% amplitude. Next, serially 10-fold dilute the sonicated lysate, harvested from a 10 to the first to 10 to the sixth concentration in fresh DMEM and add one milliliter of each dilution to individual confluent wells of a protein kinase-R competent cell line. Place the cells in the cell culture incubator for one hour before replacing the supernatants with fresh medium and returning the cells to the cell culture incubator. After 24 to 48 hours, identify the recombinant viruses by fluorescence microscopy. Plaques from recombinant viruses express red fluorescence due to integration of the mCherry-E3L fusion gene. Plaque purify the recombinant viruses three times on wild type RK13 cells. After three rounds of plaque purification, infect RK13+E3L+K3L cells with serial dilutions of the plaque lysate. To identify the collapsed viruses, by fluorescence microscopy using an appropriate imaging system equipped with GFP and RFP filter cubes. Then plaque purify green-only VC-R4, or colorless E3L plaques three times on RK13+E3L+K3L cells. Ensuring that no plaques fluoresce red. Infect the cells with at least 100 plaque forming units to increase your chances of identifying a colorless plaque. In rare cases, multiple rounds of infection might be required. Red fluorescent plaques in protein kinase-R competent RK13 cells are indicative of viral expression of mCherry-E3L. And colorless plaques or plaques expressing only eGFP in RK13+E3L+K3L cells confirm the collapse of the mCherry-E3L selection marker.The recombinant virus VC-R4, which lacks both protein kinase-R antagonists cannot replicate in protein kinase-R competent RK13 cells while the parent virus vP872, which expresses E3L is replication competent. To confirm that this inability to replicate in RK13 cells was only due to the loss of E3L, enhanced GFP was replaced with E3L in the VC-R4 virus to generate a relevant virus using the same selection protocol.Interestingly, while making this virus, colorless plaques consistent with collapse of the mCherry-E3L selection marker were identified prior to selection in RK13+E3L+K3L cells that are generally required to select scarless recombinants, likely because of the extended sequence identity between the mCherry-E3L recombination cassette and the E3L gene being inserted into VC-R4. On average 12.6% of progeny virions underwent recombination with the transfected plasmid, similar to previously reported frequencies.Here, the frequency of colorless plaques relative to the total plaques RK13+E3L+K3L cells is shown, demonstrating that the rate of collapse and the loss of the mCherry-E3L selection marker occurred at an approximately 1.8% frequency. In the first stage using PKR competent cells ensures that all of the plaques will contain recombinant virus. In the second stage using PKR deficient cells enables the detection of recombinant virus with a collapsed mCherry-E3L locus.This approach allows us to rapidly generate viruses containing exogenous genes, for example, for vaccine production offer the expression of different viral PKR antagonists to facilitate the analysis of species-specific interactions with PKR from various hosts.

rapid-seamless-generation-recombinant-poxviruses-using-host-range

Research

JoVE Journal

Immunology and Infection

Here we describe a protocol based only on cell infection, which improves the efficiency of recombinant parvovirus production by more than 100 fold in comparison to other protocols in use. This protocol relies on the use of a novel adenovirus 5-based helper containing the parvovirus VP transcription unit (Ad-VP).

Efficient Recombinant Parvovirus Production with the Help of Adenovirus-derived Systems

A rapid and modular protocol for the generation of recombinant vaccinia viruses expressing fluorescently tagged proteins simultaneously using the method of transient dominant selection is described here.

Methodology for the Efficient Generation of Fluorescently Tagged Vaccinia Virus Proteins

We describe the usage of a fluorescent reporter vaccinia virus that enables real-time measurement of viral infectivity and gene expression through the stage-specific expression of spectrally distinct reporter fluorophores. We detail a plate-based method for accurately identifying the stage at which virus replication is affected in response to small molecule inhibition.

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression

Vaccinia virus (VV) has been widely used in biomedical research and the improvement of human health. This article describes a simple, highly efficient method to edit the VV genome using a CRISPR-Cas9 system.

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Herpesvirus of turkeys (HVT) is widely used as a vector platform for the generation of recombinant vaccines against a number of avian diseases. This article describes a simple and rapid approach for the generation of recombinant HVT-vectored vaccines using an integrated NHEJ-CRISPR/Cas9 and Cre-Lox system.

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing

We describe a method for generating and amplifying genetically modified respiratory syncytial viruses (RSVs) and an optimized plaque assay for RSVs. We illustrate this protocol by creating two recombinant viruses that respectively allow quantification of RSV replication and live analysis of RSV inclusion bodies and inclusion bodies-associated granules dynamics.

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation of recombinant rotaviruses from plasmid DNA provides an essential tool for the study of rotavirus replication and pathogenesis, and the development of rotavirus expression vectors and vaccines. Herein, we describe a simplified reverse genetics approach for generating recombinant rotaviruses, including strains expressing fluorescent reporter proteins.

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins

Here, we present a protocol to obtain the pVAX1-PRRSV expression vector by introducing suitable restriction sites at the 3' end of the inserts. We can linearize the vector and join DNA fragments to the vector one by one through homologous recombination technology.

A Seamless Cloning Approach for Porcine Reproductive and Respiratory Syndrome Virus Expression Vector Construction

Rescue of influenza A viruses from plasmid DNA is a basic and essential experimental technique that allows influenza researchers to generate recombinant viruses to study multiple aspects in the biology of influenza virus, and to be used as potential vectors or vaccines.

Generation of Recombinant Influenza Virus from Plasmid DNA

This protocol describes a simple adhesive-tape-based approach for sampling of tomato and other fresh produce surfaces, followed by rapid whole cell detection of Salmonella using fluorescence in situ hybridization (FISH).

Combination of Adhesive-tape-based Sampling and Fluorescence in situ Hybridization for Rapid Detection of Salmonella on Fresh Produce

Learn scarless recombinant vaccinia virus generation using host-range selection and fluorescent markers. This method enables efficient genetic modification for vaccine development and gene expression studies.

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Explore More Videos